Sugi Predict

Sugi Predict / Compounds / SCHEMBL26875

SCHEMBL26875

SCHEMBL26875

COc1[c]cc2c(Nc3ccc(F)c(Cl)c3)nc(C(N)=O)nc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A1 P68400 4/20 0.49
▸ CSF1R P07333 1/20 0.46
▸ CSNK2A2 P19784 2/20 0.44
▸ CSNK2B P67870 2/20 0.44
▸ EGFR P00533 11/20 0.44
▸ KDR P35968 3/20 0.44
▸ ERBB2 P04626 3/20 0.43
▸ ERBB4 Q15303 1/20 0.43
▸ AURKA O14965 2/20 0.43
▸ INSR P06213 1/20 0.43
▸ FBP1 P09467 1/20 0.43
▸ PDGFRB P09619 1/20 0.43
▸ FLT4 P35916 1/20 0.43
▸ CLK1 P49759 1/20 0.43
▸ EPHB4 P54760 1/20 0.43
▸ TEK Q02763 1/20 0.43
▸ AURKB Q96GD4 1/20 0.43
▸ ERBB3 P21860 1/20 0.43
▸ DUS2 Q9NX74 1/20 0.43
▸ RPS6KB1 P23443 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26636 0.90 EGFR (0.47) CSNK2A1CSF1REGFRERBB2ERBB4
SCHEMBL24978 0.90 CSNK2A1 (0.43) CSNK2A1CSF1RCSNK2A2CSNK2BEGFR
SCHEMBL26592 0.89 EGFR (0.44) CSNK2A1CSF1RCSNK2A2CSNK2BEGFR
SCHEMBL24316 0.89 AURKA (0.43) CSNK2A1CSF1RCSNK2A2CSNK2BEGFR
SCHEMBL26349 0.88 EGFR (0.44) CSNK2A1CSF1REGFRERBB2ERBB4
SCHEMBL27067 0.87 EGFR (0.43) CSNK2A1CSF1RCSNK2A2CSNK2BEGFR
SCHEMBL2989950 0.87 EGFR (0.47) CSNK2A1CSF1RCSNK2A2CSNK2BEGFR
SCHEMBL2991658 0.87 EGFR (0.47) CSNK2A1CSF1RCSNK2A2CSNK2BEGFR
SCHEMBL25893 0.86 EGFR (0.42) CSNK2A1CSF1RCSNK2A2CSNK2BEGFR
SCHEMBL26112 0.86 EGFR (0.42) CSNK2A1CSF1RCSNK2A2CSNK2BEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1746999-B1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES WARNER LAMBERT CO (US) 2011-11-16 — — EP claimed
US-20110262877-A1 HEAT TREATMENT APPARATUS IHI CORPORATION (JP) 2011-10-27 — — US claimed
US-7772243-B2 4-phenylamino-quinazolin-6-yl-amides WARNER-LAMBERT COMPANY LLC (US) 2010-08-10 — — US claimed
JP-4205757-B2 — — 2009-01-07 — — JP claimed
JP-2007536368-A — — 2007-12-13 — — JP claimed
EP-1746999-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES Warner-Lambert Company LLC (US) 2007-01-31 — — EP claimed
WO-2005107758-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES WARNER-LAMBERT COMPANY LLC (US) 2005-11-17 — — WO claimed
US-20050250761-A1 such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis PFIZER INC 2005-11-10 — — US claimed
US-20230001008-A1 COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES KUMQUAT BIOSCIENCES INC. 2023-01-05 — — US disclosed
WO-2021035096-A1 COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES KUMQUAT BIOSCIENCES INC. (US) 2021-02-25 — — WO disclosed
US-8623883-B2 4-phenylamino-quinazolin-6-yl-amides WARNER-LAMBERT COMPANY LLC (US) 2014-01-07 — — US disclosed
US-20130274275-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES WARNER-LAMBERT COMPANY LLC 2013-10-17 — — US disclosed
US-8466165-B2 4-phenylamino-quinazolin-6-yl-amides WARNER-LAMBERT COMPANY LLC (US) 2013-06-18 — — US disclosed
US-7772243-B2 4-phenylamino-quinazolin-6-yl-amides WARNER-LAMBERT COMPANY LLC (US) 2010-08-10 — — US disclosed
US-20100190977-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES PFIZER INC. 2010-07-29 — — US disclosed
EP-1746999-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES Warner-Lambert Company LLC (US) 2007-01-31 — — EP disclosed
WO-2005107758-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES WARNER-LAMBERT COMPANY LLC (US) 2005-11-17 — — WO disclosed
US-20050250761-A1 such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis PFIZER INC 2005-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230001008-A1 COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES CD2BP2, CD47, CD74 CSNK2A1 1577/4885CSF1R 1753/4885CSNK2A2 1380/4885
US-20100190977-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES HRH4, HRH3, HRH2 CSNK2A1 2174/4885CSF1R 1626/4885CSNK2A2 2391/4885
US-20050250761-A1 such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis JAK1, JAK2, EDNRA CSNK2A1 506/4885CSF1R 420/4885CSNK2A2 839/4885
US-20130274275-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES HRH4, HRH3, HRH2 CSNK2A1 2174/4885CSF1R 1626/4885CSNK2A2 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.